Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

– Achieved significant clinical progress for UltraCAR-T® and AdenoVerse™ investigational therapeutics in 2022 – – Presented positive clinical data for...

Related Keywords

Minnesota ,United States ,Mayo Clinic In Rochester ,American ,Harry Thomasian Jr ,Precigen Ultra ,Stevenm Harasym ,Precigen Adenoverse ,Helen Sabzevari ,Drug Administration ,Nasdaq ,Company Rd Day ,American Society Of Hematology ,Exchange Commission ,Prnewswire Precigen Inc ,Key Program ,Precigen Inc ,Complete Response ,Trans Ova Genetics ,Dose Level ,American Society ,Annual Meeting ,Mayo Clinic ,Dose Expansion Study ,Advanced Hematologic ,Solid Tumor Malignancies ,Results Compared ,Prior Year ,Advancing Medicine ,Sleeping Beauty ,Annual Report ,Precigen ,Nc ,